AIIRA VA Recommendations for Use

In a randomised, double-blind, add-on study [CS8635-A-E303] in 808 patients (99.9 % Caucasian patients) not adequately controlled after 8-weeks therapy with olmesartan medoxomil 40 mg plus amlodipine 10 mg dual combination, treatment with SEVIKAR HCT resulted in numerically additional seated blood pressure reduction of -1.8/-1.0 mmHg when treated with SEVIKAR HCT 40 mg/10 … ................
................